LABORATORY RESEARCH Inhibition of NF-Kappa B Signaling Restores Responsiveness of Castrate-Resistant Prostate Cancer Cells to Anti-Androgen Treatment by Decreasing Androgen Receptor-Variant Expression Researchers show that the activation of classical nuclear factor-kappa B (NF-κB) signaling increases the expression of androgen receptor splicing variants (ARVs) in prostate cancer (PCa) cells and converts androgen-sensitive PCa cells to become androgen-insensitive, whereas downregulation of NF-κB signaling inhibits ARV expression and restores responsiveness of castration-resistant prostate cancer to anti-androgen therapy. [Oncogene] Abstract WNT5A Has Anti-Prostate Cancer Effects In Vitro and Reduces Tumor Growth in the Skeleton In Vivo Using different osteotropic human prostate cancer cell lines, the influence of WNT5A overexpression and knockdown on proliferation, migration, and apoptosis was assessed. In vitro, WNT5A overexpression induced prostate cancer cell apoptosis and reduced proliferation and migration, whereas WNT5A knock-down showed opposite effects. [J Bone Miner Res] Abstract Supraphysiological Androgen Levels Induce Cellular Senescence in Human Prostate Cancer Cells through the Src-Akt Pathway Scientists describe that supraphysiological levels of androgens induce cell cycle arrest and markers of cellular senescence in human prostate cancer cells, which may in part explain the growth inhibitory role of androgens. [Mol Cancer] Full Article Targeting IL-6 and RANKL Signaling Inhibits Prostate Cancer Growth in Bone Using the human prostate cancer cell line, PC3, scientists identified two novel signaling pathways acting between cells of the osteoblast lineage and cancer cells. Exposure to RANKL stimulated the expression and release of IL-6 by PC3 cells in vitro. [Clin Exp Metastasis] Abstract Epibrassinolide-Induced Apoptosis Regardless of p53 Expression via Activating Polyamine Catabolic Machinery, a Common Target for Androgen Sensitive and Insensitive Prostate Cancer Cells Researchers previously showed that epibrassinolide (EBR) induced apoptosis by activating polyamine catabolic pathway, which lead to the accumulation of cytotoxic compounds such as hydrogen peroxide and aldehydes in LNCaP and DU 145 prostate cancer cells. However, they found that LNCaP prostate cancer cells expressing functional androgen receptor (AR) was found more sensitive to EBR than those with non-functional AR. [Prostate] Abstract Viriditoxin Regulates Apoptosis and Autophagy via Mitotic Catastrophe and Microtubule Formation in Human Prostate Cancer Cells Viriditoxin (VDT) produced dose-dependent cytotoxicity against human prostate cancer cells. Treatment with VDT promoted both apoptosis and autophagy in LNCaP cells. [Int J Oncol] Abstract Amyloid Precursor Protein Regulates Migration and Metalloproteinase Gene Expression in Prostate Cancer Cells Scientists explored a pathophysiological role for amyloid precursor protein (APP) in prostate cancer cells using siRNA targeting APP (siAPP). The proliferation and migration of LNCaP and DU145 prostate cancer cells were significantly suppressed by siAPP. [Biochem Biophys Res Commun] Abstract Immediate and Transient Phosphorylation of the Heat Shock Protein 27 Initiates Chemoresistance in Prostate Cancer Cells Researchers investigated the effects of heat shock protein (HSP)27 phosphorylation on prostate cancer cell growth underlying docetaxel treatment. Cell counting revealed significantly reduced cell growth during docetaxel treatment as a result of both activation of mitogen-activated protein kinase p38 and protein kinase D1, and, most importantly, the overexpression of the phosphorylation-mimicking mutant HSP27-3D. [Oncol Rep] Abstract Association of Increased Levels of TGF-β1 and p14ARF in Prostate Carcinoma Cell Lines Overexpressing Egr-1 Scientists examined the effect of the overexpression of early growth response gene (Egr-1) on transforming growth factor β-1 (TGF-β1) and p14ARF levels, in PC-3 and LNCaP prostate carcinoma cell lines. [Oncol Rep] Abstract CLINICAL RESEARCH Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study Cabozantinib, an oral inhibitor of multiple receptor tyrosine kinases such as MET and VEGFR2, was evaluated in a Phase II nonrandomized expansion study in castration-resistant prostate cancer. [J Clin Oncol] Abstract Circulating Tumor Cell Telomerase Activity as a Prognostic Marker for Overall Survival in SWOG 0421: A Phase III Metastatic Castration Resistant Prostate Cancer Trial Researchers hypothesized that circulating tumor cells (CTC) telomerase activity (TA) may be prognostic of overall survival in metastatic castration resistant prostate cancer. To test this, they used a novel Parylene-C slot microfilter to measure live CTC TA in S0421, a Phase III SWOG-led therapeutic trial. [Int J Cancer] Abstract |